{
    "eid": "2-s2.0-84912137896",
    "title": "Metformin does not improve survival in patients with hepatocellular carcinoma",
    "cover-date": "2014-11-14",
    "subject-areas": [
        {
            "$": "Gastroenterology",
            "@code": "2715"
        }
    ],
    "keywords": [
        "Diabetes",
        "Hepatocellular carcinoma",
        "Lactic acidosis",
        "Liver disease",
        "Metformin",
        "Survival"
    ],
    "authors": [
        "Mamatha Bhat"
    ],
    "citedby-count": 32,
    "ref-count": 24,
    "ref-list": [
        "Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity",
        "Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States",
        "Hepatocellular carcinoma: Recent trends in the United States",
        "Sorafenib in advanced hepatocellular carcinoma",
        "Phase 1/2 study of everolimus in advanced hepatocellular carcinoma",
        "Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma",
        "Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells",
        "Metformin prevents tobacco carcinogen-induced lung tumorigenesis",
        "Metformin inhibits melanoma development through autophagy and apoptosis mechanisms",
        "Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3)",
        "Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: Population-based and in vitro studies",
        "Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease",
        "Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis",
        "Diabetes and cancer: A consensus report",
        "Diabetes increases the risk of hepatocellular carcinoma in the United States: A population based case control study",
        "Liver disease and diabetes mellitus",
        "The insulin and insulin-like growth factor receptor family in neoplasia: An update",
        "Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth",
        "Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis",
        "Int J Oncol",
        "In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma",
        "Association between metformin therapy and mortality after breast cancer: A population-based study",
        "Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin",
        "Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes"
    ],
    "affiliation": [
        {
            "affiliation-city": "Rochester",
            "affilname": "Mayo Clinic College of Medicine and Science",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Montreal",
            "affilname": "Centre Universitaire de Sant\u00e9 McGill",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Rochester",
            "affilname": "Mayo Clinic",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "National Institutes of Health",
        "National Institutes of Health",
        "National Center for Advancing Translational Sciences",
        "National Center for Advancing Translational Sciences"
    ]
}